The in vitro activity of cefepime was compared with those of ceftazidime, cefotaxime, and cefpfrome against amlnoglycoside..resistaAit gram-negative bacteria. Cefepime was the most active cephalosporin, with a MIC for 90% of strains tested for all non-Pseudomonas aeruginosa species of c4 txg/mI. No cefepime resistance was encountered among members of the family Enterobacteriaceae. Of the 40 aminoglycoside-resistant P. aeruginosa isolates, 15% were resistant to cefepime, compared with 18% for ceftazidime, 30% for cefpirome, and 35% for celotaxime. Synersm between cefepime and amikacin was observed and occurred most frequently in P. aeruginosa strains resistant to. cefepime but susceptible to amikacin. In no case did cefepime and amikacin exhibit antagonism against P. aeruginosa.
Broad-spectrum cephalosporins and aminoglycosides are highly active against aerobic gram-negative bacteria. However, resistance to these agents has developed during their clinical use. Resistance to the expanded-spectrum cephalosporins may result in up to one-half of patients infected with Pseudomonas aeruginosa, Entierobacter spp., or Serratia marcescens during or after therapy and is primarily,the result of p-lactamase overproduction (5, 16) . Resistance to specific aminoglycosides with the exception of amikacin has been observed in medical centers where usage was extensive (2, 7. 11).
Cefepime is geaerally active against gram-negative bacteria resistant to other br.oad-spectrum cephalosporins. No cefepime resistance was observed among cefotaxime-and/or ceftazidime-resistant members of the family -Enterobacteriaceae (6, 8) . Even With a group of cefotaxime-and/or ceftazidime-resistant P. aeruginosa strains, 81% of the strains continued to be susceptible to cefepime (6) .
In this study, we determined the activities of cefepime and other broad-spectrum cephalosporins against 240 Synergy studies with cefepime plus amikacin were performed by the checkerboard microtiter method with 18 P. aeruginosa strains. (10) . Synergy was defined as a fractional inhibitory concentration index of c0.5, and antagonism was defined as a fractional inhibitory concentration index of >4.
Of the 240 aminoglycoside-resistant bacteria, 222 were resistant to gentamicin (MIC, .16 pug/ml), 212 were resistant to tobramycin (MIC, .64 ,ug/ml), and 27 were resistant to amikacin (MIC, -64 ,ug/ml). Overall, cefepime was more active than cefpirome, ceftazidime, and cefotaxime against the aminoglycoside-resistant strains ( Table 1) . The MICs for 90% of strains tested of cefotaxime for S. marcescens, Enterobacter cloacae, Escherichia coli, and P. aeruginosa were 64 to 128 ,ug/ml, which is in the resistant interpretative range for cefotaxime (14) . When MICs of .64 ,ug/ml for cefotaxime and .32 ,ug/ml for cefepime, cefpirome, and ceftazidime were used as the breakpoints for resistance (14) , NOTES Similarly, none of the nine cefepime-sensitive P. aeruginosa strains showed synergism with amikacin and cefepime.
Our observation that in vitro synergy between cefepime and amikacin occurred most frequently in P. aeruginosa strains susceptible to amikacin but resistant to cefepime was in accord with those of Moody et al. (13) , who reported that synergy was most often produced in P. aeruginosa strains for which the amikacin MIC was <16 jig/ml and the cefepime MIC was .16 jig/ml. This trend has also been observed with cefepime and tobramycin, where synergy was more likely demonstrated with cefepime-resistant isolates that were susceptible to tobramycin (3). As with the infrequent demonstration of synergism between cefepime and amikacin in P. aeruginosa strains for which the amikacin MIC was .32 ,ug/ml, a similar failure to demonstrate synergy has been reported for amikacin plus ceftazidime (3) and for other aminoglycoside antipseudomonal penicillin combinations (4) against aminoglycoside-resistant P. aeruginosa. Higher synergism rates of 43 to 68% were reported in one 'study (1) for amikacin-resistant P. aeruginosa with various amikacin-P-lactam combinations.
Regardless, in this and other studies (4, 13), cefepime did not display antagonism with aminoglycosides. In a Qomparative study of cefepime plus amikacin, ciprofloxacin plus amikacin, and imipenem plus amikacin, Moody et al. (13) noted more antagonism than synergism with the last two combinations and no antagonism against P. aeruginosa with the cefepime-amikacin combination.
In summary, cefepime was the most active of the expanded-spectrum cephalosponns against aminoglycoside-resistant gram-negative bacteria. Cefepime can be synergistic with amikacin in inhibiting P. aeruginosa. This synergism may be more frequent 'with cefepime-resistant, amikacinsusceptible P. aeruginosa strains.
